Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. - Wikidata - awgldk - TriplyDB

Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality.

Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality.

http://www.wikidata.org/entity/Q37460355

about

Role of Toll-Like Receptor Signaling in the Pathogenesis of Graft-versus-Host Diseases The role of pattern-recognition receptors in graft-versus-host disease and graft-versus-leukemia after allogeneic stem cell transplantation Indoleamine 2,3 dioxygenase in intestinal disease TLR/MyD88-mediated Innate Immunity in Intestinal Graft-versus-Host Disease Advances in graft-versus-host disease biology and therapy.The role of dendritic cells in tissue-specific autoimmunity.Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new.Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation A CD8 T cell/indoleamine 2,3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus.Innate immunity and transplantation tolerance: the potential role of TLRs/NLRs in GVHD Induction of indoleamine 2, 3-dioxygenase in human dendritic cells by a cholera toxin B subunit-proinsulin vaccine.Amino acid catabolism: a pivotal regulator of innate and adaptive immunity.Indoleamine 2,3-dioxygenase in human hematopoietic stem cell transplantation.Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells.Allogeneic mesenchymal stem cells inhibited T follicular helper cell generation in rheumatoid arthritis.Engineering DNA nanoparticles as immunomodulatory reagents that activate regulatory T cells.Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1).The potential role of indoleamine 2,3 dioxygenase (IDO) as a predictive and therapeutic target for diabetes treatment: a mythical truth.Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation.The gastrointestinal tract: properties and role in allogeneic hematopoietic stem cell transplantation.Indoleamine 2,3-dioxygenase and metabolites protect murine lung allografts and impair the calcium mobilization of T cells.IDO in human gut graft-versus-host disease.Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity.Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration.Homing in on acute graft vs. host disease: tissue-specific T regulatory and Th17 cells.Gene expression changes in HLA mismatched mixed lymphocyte cultures reveal genes associated with allorecognition.Indoleamine 2,3-dioxygenase: is it an immune suppressor?Hypoxia and Mucosal Inflammation.miR-153-3p, a new bio-target, is involved in the pathogenesis of acute graft-versus-host disease via inhibition of indoleamine- 2,3-dioxygenase.Non-hematopoietic cells contribute to protective tolerance to Aspergillus fumigatus via a TRIF pathway converging on IDO.Concise review: hitting the right spot with mesenchymal stromal cells.Danger signals activating innate immunity in graft-versus-host disease.Role of gut microbiota in graft-versus-host disease.Clinical perspectives for regulatory T cells in transplantation tolerance.Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.New functions of protein kinase Gcn2 in yeast and mammals.Pathogenesis of graft-versus-host disease: innate immunity amplifying acute alloimmune responses.

P2860

Q26741220-0F1F9794-E913-4F94-BE0F-258081D1B996 Q26824436-D9C6940E-5B41-488D-B4C5-B4B6C61DAB0B Q27025063-059BA422-3E59-4277-91AA-858EDB266DB7 Q33835099-E67583FF-996C-4D13-B625-75FC4F12C3D0 Q34031916-43874AD8-324A-4D5E-B9FB-59F14B38D5E2 Q34422017-4AB266D3-E1B1-471E-859D-B99B5B6D4E59 Q34754302-458BF86C-81ED-41D6-9947-B4CD5A1BDE32 Q34973719-E9FAAC95-962B-4886-8DDA-170AB624E519 Q35023185-0DDBF140-5CB0-4AB0-BBDA-A69349436780 Q35084400-C25905B5-3E16-4CD3-B467-DAF1184DDA7F Q35122841-6BA04F4A-2C51-4779-A4B3-A44D09714732 Q35261125-739F0F4E-9BC5-4655-9FC9-C012F779F19E Q35366857-543302D6-313F-43FA-804C-E37E05E5D12D Q35586614-D4942A12-55C8-4288-9B86-75A5D00BA907 Q35753251-ADB4ACF1-BB9D-448C-A68C-DC1C1C3AB62B Q35909695-A903E430-DEF4-4319-99F2-04309A2FA95C Q35935923-85E5670B-00A7-48D7-98FD-84E397F0EB74 Q35949475-A8955768-7A30-4E89-AA73-9A756B84600C Q36014986-92EE2624-C24C-495B-B761-1B9F6CC1B52A Q36041377-B7A73601-0BF9-47C7-9FAC-9672BF9B8D9D Q36117580-333C9ECC-129F-4FED-8014-3B8ADB154E50 Q36130498-F7D9EC67-D9EA-444D-BB34-BF3F13C7AA67 Q36264109-A9088163-0198-4A3E-8123-32F33E8F6354 Q36369985-5F8490A6-0337-47B5-87C9-66409F9458DF Q36590698-5E2C0B7A-9F32-4175-91B7-E5188430E837 Q36821053-C5833EAE-2F88-4E06-8254-0FBC5E45D9D5 Q37186477-FBB82FCD-3C24-4988-BCB6-2113BEF127CF Q37223366-5F1C814A-C9A9-41B4-8E95-716ED1FEDDE4 Q37320319-647B2698-2A42-4E03-A946-F0CD995EB4DB Q37362632-7036D151-125E-4CF4-A1EB-3EF5B5CCD5C2 Q37550577-4F83DA34-EB23-4A93-965C-C89D9BA5DDB4 Q37565461-A86E1F85-2381-4037-928A-43E6E06CC262 Q37729196-A8C41380-9D32-4377-9648-357E014064D6 Q37769501-11C9ADE1-4FF5-421D-B22D-00954A2F5978 Q37875779-5504E8EA-C309-44FE-B479-2CD31F5F5D4B Q37887810-3FC81AA9-2C7B-4805-B290-38077734C4D6 Q37912653-E618DFBB-2DCC-41E5-8795-5E4BBEE57676 Q38047057-98367407-0334-4610-A766-B52183BF129B Q38057995-38B27D7A-2714-44A8-A31F-94F6A0A7490F Q38132090-E97C1196-F224-4401-B4FC-35AE10D37388

P2860

Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality.

http://www.wikidata.org/entity/Q37460355

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 October 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Inducing the tryptophan catabo ...... host disease (GVHD) lethality.

@en

Inducing the tryptophan catabo ...... host disease (GVHD) lethality.

@nl

type

label

Inducing the tryptophan catabo ...... host disease (GVHD) lethality.

@en

Inducing the tryptophan catabo ...... host disease (GVHD) lethality.

@nl

prefLabel

Inducing the tryptophan catabo ...... host disease (GVHD) lethality.

@en

Inducing the tryptophan catabo ...... host disease (GVHD) lethality.

@nl

P1433

Q37460355-E1EC4C94-949F-4144-A433-E4E3AB2F6FF1

P1476

Q37460355-B83AC34E-AD4B-41E7-BC09-0B89AF7C75B1

P2093

Q37460355-00F9748C-5D93-4216-953C-780A9077498C

Q37460355-4F8D75F5-A00A-4429-AE8B-B38CBE8BF8FB

Q37460355-A3E0B5C6-47D9-4C0A-8C04-3253D146F29E

Q37460355-FA21C618-55B7-4A0C-BE54-A133E0400BF3

P2860

Q37460355-003A5DC9-D81E-450F-ADD4-4D9D18346D6B

Q37460355-029A5ACA-431A-4FDB-B848-D1BDF0E71EC6

Q37460355-0AE8E851-6F61-44B1-A1D7-2FFA84227D21

Q37460355-1B98EF59-FA47-4BD3-965A-67EDAC61288C

Q37460355-2BA41544-71E5-41E0-B484-3D543C5B0F28

Q37460355-2C63C20B-D2EB-45A5-8AC4-1A7F664DDC79

Q37460355-318B59DD-6FCF-49B4-92AA-3B7C35EDDE13

Q37460355-3898EAAC-C0CC-483B-A834-287687B77ADA

Q37460355-4DEE5CB9-D91F-4D8F-9C03-7C7D5B82AC85

Q37460355-547BBBAA-A005-4F46-87C1-61FAE1E2D3F1

P304

Q37460355-16086E35-E280-4ACC-BC0B-B02C84EEA348

P31

Q37460355-8F07B824-0EE5-478A-84D2-51B0B832A067

P356

Q37460355-F2BA17CC-8FC4-4170-86AF-8B26E8486428

P407

Q37460355-7AB3915C-E96B-43AD-8AB2-F049BE7ED63B

P433

Q37460355-D6BBC0D9-6E4D-47A6-8D80-1E0C1F81B4A9

P478

Q37460355-5E90EBD9-C45A-47AE-ADA8-7840BEDEDBAE

P50

Q37460355-0E5123FB-EFE9-44BD-8F27-5F8F5532BCF0

Q37460355-B95B96F3-23DD-47B8-B26B-1D93A7BA2779

P577

Q37460355-23A7B467-397E-4827-8C84-874F2F4F1058

P5875

Q37460355-A46E1DDC-25C2-4E85-80BF-026CF0E25959

P698

Q37460355-A260AE16-550B-412A-ADA0-454E40337852

P932

Q37460355-08E36931-8BDF-4919-9C02-1FB682758A57

P356

BLOOD-2009-06-227587

P1433

P1476

Inducing the tryptophan catabo ...... host disease (GVHD) lethality.

@en

P2093

Andrew L Mellor

http://www.w3.org/2001/XMLSchema#string

Christoph Bucher

http://www.w3.org/2001/XMLSchema#string

David H Munn

http://www.w3.org/2001/XMLSchema#string

Lisa K Jasperson

http://www.w3.org/2001/XMLSchema#string

P2860

Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase–dependent DC functions and regulates experimental graft-versus-host disease in mice

Prevention of allogeneic fetal rejection by tryptophan catabolism

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific

Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells

Inhibition of experimental asthma by indoleamine 2,3-dioxygenase

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis

P304

5062-5070

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-06-227587

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P50

Angela Panoskaltsis-Mortari

P577

2009-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38011164

http://www.w3.org/2001/XMLSchema#string

P698

19828695

http://www.w3.org/2001/XMLSchema#string

P932

2788979

http://www.w3.org/2001/XMLSchema#string